Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, discusses exciting updates on BTK inhibitors for chronic lymphocytic leukemia (CLL) from the virtual European Hematology Association (EHA) meeting 2021. In particular, Dr Scarfò highlights a direct comparison between acalabrutinib and ibrutinib in patients with relapsed/refractory CLL and associated cardiac toxicities. Dr Scarfò also talks on the CAPITIVATE study (NCT02910583) and a study from the HOVON group, both of which are investigating measurable residual disease (MRD)-driven treatment with ibrutinib and venetoclax. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.